Purity: SDS-PAGE

Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC

The purity of Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) is 100%, determined by SEC-HPLC.

Bioactivity: FACS

SNU-16 cells were stained with Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.5368 ug/mL.

Function: ADCC

Anti-FGFR2/CD332 Reference Antibody (bemarituzumab) induced ADCC activity was evaluated using Human FGFR2 HEK293 Reporter Cell.The max induction fold was approximately 25.

Function: ADCC

Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab) -ADCC luciferase Assay on KATOIII cells. The maximum suppression factor is approximately 14.

Research in vivo

Bemarituzumab inhibited the tumor growth of SNU-16 on Balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 29.7% at 2 mpk at D62.

-25~-15℃保存，有效期1年。